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Introduction
The United States currently holds approximately
1,000 chimpanzees in research facilities (1), and
stands alone in the world as the only country
actively conducting invasive research on captive
chimpanzees to any significant degree. Many gov-
ernments worldwide have taken legislative steps
to ban or severely limit experiments on great apes
predominantly for ethical reasons, based on our
knowledge of the cognitive and emotional capaci-
ties of chimpanzees (2). 
The ethical argument for a ban on chimpanzee
research is now being progressively augmented by
scientific evidence revealing Pan troglodytes to be
a poor research model for human biology and med-
icine. Such evidence constituted the main rationale
behind the decision of the Dutch government to
disband the last chimpanzee population used for
research in Europe, and to prohibit any further sci-
entific research or testing on chimpanzees and
other great apes (3). The Dutch Minister of
Science, Loek Hermans, stated, “In recent years it
has become clear that the need for the use of chim-
panzees for research into malaria and HIV has
rapidly diminished and is of limited importance.
The progression of illness in chimpanzees is
starkly different from that of humans, which
makes the chimpanzee an unsuitable ‘model’.” (4).
Despite the decisions of these governments, the
evidence that underpins them, as well as wide-
spread public opinion (5), chimpanzee research
remains controversial. Some advocates claim that
chimpanzee experimentation is indispensable in
the fight against major human diseases such as
AIDS, hepatitis and cancer, without which treat-
ments for human disease will not be realised (6).
Given the ethical and financial costs of chimpanzee
research, and the considerable doubt regarding its
efficacy and scientific validity, these claims cannot
be made lightly. Similarly, solid scientific evidence
must support the opinions of those who believe
chimpanzee research to be unscientific and/or
unethical. To date, evidence has been published
that demonstrates the redundancy and lack of sci-
entific worth of chimpanzee research (7, 8), and
that chimpanzee use in AIDS vaccine research is
not predictive for human vaccine response and effi-
cacy assessment (9). Further, studies from an eth-
ical perspective have revealed the existence of
Post-Traumatic Stress Disorder in ex-research
chimpanzees now in sanctuary (10), and have
detailed the physical and psychological traumas
suffered by chimpanzees that have been raised in
various human/chimpanzee contexts then used in
research — and the chimpanzees’ consequent abil-
ity to recover from such trauma once in sanctuary
(11).
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Cancer was chosen as the focus of this investiga-
tion because it is a major and growing contributor
to the burden of human disease worldwide — as
well as being a leading cause of premature death.
It is responsible for a quarter of all deaths in the
European Union (EU), and almost a half of deaths
in the age range 45–64 years (12). In the USA, it is
estimated that 1,437,180 new cancer cases and
565,650 deaths from cancer occurred in 2008 (13).
Given this impact, one might expect a sound scien-
tific argument for the use of chimpanzees in
research to elucidate the molecular basis of car-
cinogenicity and metastasis, and in the testing of
new therapeutics, evidenced by their widespread
use in the past. Chimpanzees share up to 96% of
our DNA (14, 15); a statistic often cited in defence
of their use experimentally. As recently as 2005, it
was claimed that chimpanzee research was “essen-
tial” in the testing of monoclonal antibody thera-
pies for cancer treatment, and had been “critical”
in the development of some such therapies to date
(6).
In this paper, the use of chimpanzees in cancer
research is described, the critical nature of such
experiments and translation to human cancer
treatment is deliberated, and the proposed need
for chimpanzees in cancer research in the future
is discussed. Diverse opinions and reasoned
debate on this important topic are as crucial as
the provision of new data to inform such debate.
Chimpanzee Use in Cancer Research:
The Search Strategy
The database GoPubMed (16) was searched for
all publications involving chimpanzees and can-
cer. Using the terms ‘Chimpanzee[TIAB]’ (locat-
ing all papers with the word ‘Chimpanzee’ in the
title and/or abstract) and ‘Neoplasms[MESH]’
(restricting those chimpanzee results to all
papers classified under the major disease cate-
gory ‘Neoplasms’ in the Medical Subject
Headings [MeSH] database), a comprehensive
overview of cancer research involving chim-
panzees and/or chimpanzee tissue/biological
material was obtained. This search strategy was
used because (a) it restricted results to papers
that were likely to be associated with chimpanzee
use more directly than a search for papers con-
taining ‘chimpanzee’ anywhere in the text, and
(b) ‘neoplasms’, a term very high in the hierar-
chical structure of MeSH headings, is more inclu-
sive and encompasses all types of benign and
malignant tumours.
Results and Analysis
This search identified 4,046 papers published
between 1968 and 2008 inclusive that contained
‘chimpanzee’ in the title or abstract, of which 354
were classified under the MeSH term ‘neoplasms’
(as identified by GoPubMed, as of 20 February
2009).
A timeline was first established to determine
whether there had been any increase or decrease
in this research over the years (Figure 1). The first
paper, published in 1968, was followed by just
three further papers in the following seven years.
From 1976, however, there has been a slow but
steady rise in cancer-related chimpanzee publica-
tions, with an average of twelve per year between
2000 and 2007 inclusive, including an outlying
increase to 22 papers in 2007. Notably, however,
just three papers were listed with a 2008 publica-
tion date, and the five-year relative research inter-
est1 increased from 0.0014% to just 0.0017% over
the past thirty years — indicating no significant
growth in this type of research since the late 1970s
(Figure 2; 16). 
The specific areas of cancer research in which
chimpanzees had been involved were then deter-
mined. The GoPubMed search described above,
sorted the chimpanzee papers into categories
based on the MeSH disease-categories with
which they were associated. Though the cate-
gories overlap and the papers are often associ-
ated with more than one category, the data are
revealing (Figure 3). There is a very ‘hepatic’
aspect to the results, with 51 associations with
hepatitis, 43 with liver neoplasms, and 40 with
hepatocellular carcinoma (HCC). In addition,
there were 39 papers associated with leukaemia
and 13 with T-cell leukaemia, plus 20 papers
associated with melanoma. The remaining
papers largely comprised of reports of tumours in
chimpanzees, molecular biological investigations
of genes and biochemical pathways that affect
cell/tumour growth, and investigations of puta-
tive cancer therapies, among others.
Reports of chimpanzee tumours
Fourteen papers were basic reports of tumours in
chimpanzees, with no direct relevance to human
cancer. Seven of these papers reported malignant
tumours, five described benign tumours, and two
papers described tumours that can be of either
type. The tumours described in these fourteen
papers comprised: a report of a leiomyoma and an
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1Weighted publications per year (subject specific)/total weighted publications per year (in PubMed).
Weighted publications per year = number of publications per year multiplied by relevance factors (as defined by
PubMed).
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endometrial stromal tumour (17); pulmonary
myeloproliferative malignant neoplasms (18);
ovarian Sertoli-Leydig cell tumour (arrhenoblas-
toma) (19) and fibrothecomas (20); a nasopharyn-
geal carcinoma (21); malignant melanoma (22);
hepatocellular carcinoma (23) associated with
hepatitis C virus (24) or Schistosoma mansoni
infection (25); renal carcinoma (26); anaplastic
large cell lymphoma (27); adenoma of the gall-
bladder (28); focal nodular hyperplasia and
myelolipoma (23); gastrointestinal stromal
tumour (29); and nevus lipomatosus cutaneous
superficialis (30). 
These reports, which were deemed worthy of
inclusion in peer-reviewed journals because they
were unprecedented accounts of different tumour
types in chimpanzees, illustrate their rarity. This
is openly acknowledged in the abstracts — for
example, Porter et al. (23) state, “Hepatic neopla-
sia is rare in chimpanzees. Only four hepatic neo-
plasms have been reported in chimpanzees, three
of which were associated with viral hepatitis.”
Genetic or molecular biological 
investigations
Many papers described genetic and molecular bio-
logical investigations constituting ‘basic research’
on the genes and associated biological pathways
associated with tumour development and cancer,
such as cell growth/division and apoptosis (31–81).
In many cases, the association with chimpanzees
did not involve whole-animal research on captive
animals, but instead involved the utilisation of
chimpanzee tissue and/or genetic material.
Typically, these studies centred on the investiga-
tion of human DNA and the characterisation of
human gene splicing and/or promoter elements,
and chimpanzee involvement was peripheral. For
instance, chimpanzee DNA was used compara-
tively to obtain some form of evolutionary perspec-
tive of gene variants and architecture, or to
estimate the relative importance of specific pro-
moter elements by virtue of their temporal and
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Figure 1: A timeline to illustrate the publication of papers associated with chimpanzees and
neoplasms, according to GoPubMed
The linear trendline indicates a slow but steady rise, with an average of twelve publications per year between 2000
and 2007 inclusive, including an outlying increase to 22 papers in 2007. Notably, however, just three papers were
listed with a 2008 publication date.
— An inactivating deletion in the human cytidine
monophosphate N-acetylneuraminic acid
hydroxylase (CMAH) gene is thought to ablate
the synthesis of N-glycolylneuraminic acid
(Neu5Gc), which is a prominent component of
almost all chimpanzee cell surfaces. However,
Neu5Gc is found in human cancerous cells (33),
which may be the result of an alternative syn-
thetic pathway or may be dervied from dietary
sources (34).
— Analysis of the GAGE gene family, known to be
expressed only in germ cells and some human
tumours, revealed a cluster of 15–16 duplicate
genes in humans compared to three in the chim-
panzee (35).
— Examination of sequence variation in human
succinate dehydrogenase (SDH) genes, which
have an essential role in cellular respiration,
was performed in order to gain further insights
into the multiple roles of SDH in disease pre-
disposition (36). One example includes a link
between SDH and tumour susceptibility,
notably between SDH mutations and familial
paragangliomas (37–43). This sequence analy-
sis utilised DNA from 48 human individuals
and 18 chimpanzees (obtained from a dedicated
non-human primate [NHP] DNA collection),
and identified a high degree of sequence diver-
sity in the human SDHA subunit gene com-
pared to chimpanzee SDHA: the chimpanzee
gene had 10 polymorphic variants in contrast to
21 in the human gene, and also showed 2.9-fold
lower nucleotide diversity.
— An investigation of genetic changes in NHPs of
the tumour-suppressor BRCA1 gene, which can
predispose humans to breast and ovarian can-
cers, found that most of the BRCA1 sequence
Figure 2: A timeline and linear trendline to indicate the five-year relative research interest in
papers associated with chimpanzees and neoplasms
This provides a better view of research activity and importance than an absolute number of papers, by relating
publication statistics to the overall number of scientific publications indexed by PubMed, and is calculated as:
Weighted publications per year (subject specific)/total weighted publications per year (in PubMed), where Weighted
publications per year = number of publications per year multiplied by relevance factors (as defined by PubMed). The
five-year relative research interest increased from 0.0014% to just 0.0017% during the time period over the three
decades from 1978–2008 inclusive, indicating no significant growth in this type of research since the late 1970s.
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was variable between primates (52), with pair-
wise identity between humans and chim-
panzees of aligned segments of 93–99%
(excluding indels [insertions and deletions],
which are highly prevalent in non-coding
regions).
— An examination of the distribution of Alu
repeat sequences in the genomes of NHPs (pri-
mate-specific repetitive genomic elements,
which can replicate and insert into the genome)
demonstrated that identifying the phylogenetic
roots of genetic disorders could explain the dif-
ferent susceptibility of various NHP species
(including chimpanzees) to genetic diseases
(76). Due to the association of Alu repeats with
various types of cancer via deletions, duplica-
tions, translocations, and splice variations (76),
the authors suggested similar results could be
obtained for cancer, and duly published sup-
porting data (77). This showed that the evolu-
tionary expansion of Alu repeats to new
genomic locations established new predisposi-
tions to cancer in various primate species,
based on deleterious oncogenic arrangements
and alternative splice sites, induced by Alu-
sequence insertions. Humans have an apparent
increase in Alu repeats compared to NHPs
(78–80), and greater than 2,200 AluYb8-type
repeats have been identified in the human
genome that are absent from the chimpanzee
genome (81).
— The M&M Medical Bioinformatics group in
Japan published over 20 papers between 2005
and 2007, reporting comparative integromic
(combined genomic, proteomic and bioinfor-
matic) studies of signalling pathways involved
Figure 3: Chimpanzee papers sorted into categories based on the MeSH disease-categories
with which they were associated in GoPubMed
These categories were not exclusive, and papers were often placed into more than one category. There were 51
associations with hepatitis; 43 with liver neoplasms; and 40 with hepatocellular carcinoma (HCC). In addition, 39
papers were associated with leukaemia and 13 with T-cell leukaemia, plus 20 papers associated with melanoma. The
remaining papers largely comprised of reports of tumours in chimpanzees, molecular biological investigations of
genes and biochemical pathways that affect cell/tumour growth, and investigations of putative cancer therapies,
among others.
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in tissue regeneration and carcinogenesis
(including WNT, Notch, FGF, Hedgehog and
BMP) in humans, chimpanzees, monkeys, mice
and rats (82–101). Many of the pathway compo-
nents examined were expressed and/or differen-
tially regulated in diverse types of human
tumours, and promoter binding-sites in compo-
nent genes were highly conserved across
species. In many cases in the studies by Katoh
and Katoh (82–101), the similarities of the
genes, proteins and promoter binding-sites
under examination were high between humans
and chimpanzees — as might be expected due to
their close evolutionary distance. 
Leukaemia research
Many of the papers in the search results associated
with leukaemia did not report actual human
leukaemia research. Papers were included because
they were artefacts of the literature search and
classification methods, and/or were due to non-
direct associations with cancer; these categories
were excluded from the analysis. Examples
include: references to murine leukaemia viruses
(102–108) and the biology of simian leukaemia
viruses (109); the use of leukaemic cell lines in cul-
ture (110, 111); and papers using the old name for
HIV-1, ‘HTLV-III’ (Human T-cell leukaemia virus,
type III; 112, 113).
Several papers had a more direct association
with human leukaemia research, including: an
examination of the distribution of 24kDa human
leukaemia-associated antigen, p24, on platelets
and kidney cells, by using tissue from 12 different
species including humans and chimpanzees (114);
an examination of sera from 165 NHPs of different
species, including chimpanzees, for the presence of
antibodies to HTLV (115); investigations of the
murine Friend leukaemia virus (FLV), used sub-
stantially in the past as a model for studying
genetic resistance to infection by immunosuppres-
sive retroviruses (116, 117); and a review reflecting
on studies of human retroviruses in leukaemia and
AIDS that cited chimpanzees in a discussion of the
origin of HIV (118).
Investigation or testing of new therapies
A number of papers that cited chimpanzees in
their titles and/or abstracts reported a potential
new anti-cancer therapy. TNF (tumour necrosis
factor)-related apoptosis-inducing ligand (TRAIL)
and its receptors were profiled in human and chim-
panzee tissues, to investigate recombinant TRAIL
as a therapeutic anti-cancer agent (119). TRAIL
and its three receptors (R1–R3) were differentially
expressed in a number of organs and tissues, with
notable differences between humans and chim-
panzees, though the authors concluded that its
lack of liver toxicity in chimpanzees was reassur-
ing for its proposed application in humans.
Antibodies targeting the pulmonary endothe-
lium via angiotensin-converting enzyme (ACE)
were tested in tissue from ten species of primates,
including humans and chimpanzees, for cross reac-
tivity (120). Chimpanzee/human species differ-
ences were observed, and subsequent in vivo
biodistribution studies were performed only in
macaques.
Two proposed vaccines for human epithelial-cell
tumours were developed and tested in chim-
panzees; one based on immortalised B-cells carry-
ing tumour-associated mucin (121), and a
peptide-based MUC1 vaccine (122). The former
study showed that cytotoxic T-cells recognise epi-
topes of mucin expressed on epithelial tumour
cells, but did not include tumour challenge or rejec-
tion experiments and so no therapeutic efficacy
was determined. The latter peptide approach pro-
duced positive, though transient, helper- and cyto-
toxic T-cell responses. An antigen-pulsed
dendritic-cell (DC) approach was also explored by
using chimpanzee DCs (123), in which cultured
DCs are loaded in vitro with peptide antigens and
then injected into the subject to test for immuno-
genic response. It was concluded, however, that
MUC1-specific responses might require multiple
inoculations of DCs. Chimpanzees were overlooked
for subsequent experiments in favour of transgenic
mice (124), which revealed that adjuvant-based
peptide vaccines induced humoral but not T-cell
responses with no effect on tumour growth, and
that DC-based vaccines elicited tumour rejection
responses in 90% of the mice tested.
The TNF-alpha pathway is strongly associated
with carcinogenesis and is intensely studied for the
development of therapeutics. The drug DPC333
inhibits TNF-alpha production in the blood of
humans, chimpanzees and rodents (125), and its
pharmacokinetics and pharmacodynamics in mice,
rats, dogs and chimpanzees, as well as the results
of a Phase I clinical trial in healthy humans (126),
have been determined. Notable chimpanzee/
human differences were reported, and further, the
chimpanzee performed no better than allometric
scaling with data from the other species used.
Ha6D3 monoclonal antibody was proposed for
the treatment of some leukaemias, based on in
vitro (127) and chimpanzee tests. Significant
adverse events were recorded in chimpanzees, and
this antibody has not been cited in any subsequent
publications.
Several gene therapy investigations, in which
genes are introduced directly into a patient’s cells
to treat a disease (often replacing a ‘faulty’ gene),
were described. One method of gene therapy is to
utilise viruses such as adenoviruses to deliver or
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transduce therapeutic genes as part of their natu-
ral infectious cycle. Adenoviruses from chim-
panzees have been assessed recently as an
alternative to their problematic human counter-
parts (128–130). Chimpanzee adenoviruses have
been found to transduce human dendritic cells as
efficiently as human Ad5 (131–138), though there
are differences in the behaviour and dispersal of
DCs between humans and chimpanzees at the site
of injection (139). 
Twenty melanoma investigations which used
chimpanzees were identified. For example, the
immune response and/or tolerance of chimpanzees
following exposure to different potentially thera-
peutic molecules was determined. A ‘mutein’ or
altered form of human interleukin 2 (IL-2 or
‘Proleukin’ [aldesleukin]) — used therapeutically
for advanced metastatic renal carcinoma and
melanoma (140), was tested in chimpanzees, due to
the severe systemic toxicity of native IL-2. (141).
The mutein was better tolerated in the chimpanzee
(142), but Phase I clinical (human) trial results
revealed insufficient anti-tumour activity to sup-
port further evaluation (143). Purified disialogan-
glioside GD3 elicited a specific antibody response
in chimpanzees (144, 145), but has now been
replaced by other approaches, such as conjugated
derivatives and anti-idiotypic GD3 mAbs, due to
relatively poor immunogenicity (146–149). Finally,
purified melanoma 250kDa tumour-associated
antigen (TAA; also known as HMW-MAA [high
molecular weight-melanoma associated antigen])
was also immunogenic in chimpanzees (149), and
subsequent clinical trials produced a response in
17 of 99 patients (150). In total, over 70 clinical tri-
als (not all involving chimpanzees) of anti-
melanoma therapies took place between 1992 and
2004 (151), involving a variety of proposed thera-
pies (152), yet advanced stage melanoma still has
a “dismal prognosis” and “novel therapeutic
approaches are urgently required” (151). Few ther-
apies achieve response rates greater than 25%
(153) and vaccination and augmentation of host
immunity have yielded only “limited clinical suc-
cess” (154).
Review papers
Several review papers were included in the results
of the literature search. These publications focused
on chimpanzees and cancer to varying degrees.
Those specific to areas of research discussed else-
where here have been included in their relevant
sections. In addition, a review citing the low inci-
dence of epithelial malignancy in chimpanzees, as
compared to humans, proposes one basis for this
difference to be changes in siglec expression/distri-
bution and activity (155). Siglecs (sialic acid bind-
ing Ig-like lectins) recognise sialic acid molecules,
one of which, Neu5Gc (N-glycolylneuraminic acid),
is not detectable in normal human tissues but is
abundant in most other mammals, including the
chimpanzee (156, 157). This, and other species dif-
ferences involving siglec expression, function, and
sialic-acid binding preferences, and the splenic dis-
tribution of immune effector cells such as
macrophages, has a significant impact on immune
system function and response to infectious agents
(158), and also the cell-mediated response to
malignant cells (155). 
A number of reviews focused on hepatitis C virus
(HCV), and were included in the search results
because of the association between HCV and HCC.
The outcome of HCV infection is highly variable
and dependent on a number of factors, however
(159). HCC is not an inevitable consequence of
HCV infection, nor does hepatitis research consti-
tute cancer research per se — therefore these
papers were excluded from detailed consideration.
Notably, however, a 2003 review of HCV, including
its role in HCC (160), opined that the lack of an
animal model other than the chimpanzee, along
with the lack of an efficient cell culture system,
had hampered research in this area.
Other papers
Several papers were published on melanoma
research during the 1970s, describing projects that
utilised chimpanzees to generate diagnostic
assays, rather than to investigate tumour biology
or treatment avenues. Hyperimmunisation of
chimpanzees with human melanoma cells permit-
ted the collection of antisera that contained anti-
bodies to common melanoma surface antigens and
that were cytotoxic to melanoma cell lines
(161–163). It was concluded that serologic identifi-
cation could provide a means of melanoma diagno-
sis, though a literature search did not identify this
type of approach as being in use clinically.
Following a human-based observation in which
different levels of urinary excretion of lignans and
isoflavinoid phytoestrogens were noted in post-
menopausal breast cancer patients, their presence
in the urine of chimpanzees was investigated on
the basis that chimpanzees are “remarkably resist-
ant to the carcinogenic effect of oestrogens” (164).
This study confirmed that chimpanzees excrete
both substances at high concentrations in their
urine, and the authors suggested this could help
maintain resistance against oestrogenic carcino-
genicity.
Much more recently, an entirely chimpanzee-
based study investigated the effect of diet on urinary
excretion of these compounds (165). The results
showed that diet significantly affected their excre-
tion, with diets high in carbohydrate, protein, veg-
etables, and particularly fat, causing a decrease in
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their elimination. Contemporary human-based stud-
ies are elucidating the effects of these compounds in
people. For example, proteomic and metabonomic
studies have revealed the potentially beneficial mod-
ulation of various proteins and metabolites following
isoflavone consumption (166), while several epi-
demiological analyses have suggested no significant
association between prostate or colorectal cancer
risk and total serum isoflavones or lignans (167).
Development and testing of monoclonal 
antibody (mAb) therapies for cancer
The literature search that formed the basis of this
investigation did not identify any publications
reporting the use of chimpanzees in the testing of
anti-cancer mAb therapies. It has been claimed,
however, that chimpanzee use is essential in this
respect (6). As of February 2009, almost 700 mAbs
to treat various diseases including cancers were
registered in the FDA’s clinical trials database
(ClinicalTrials.gov). A dedicated in-depth evalua-
tion of these claims is therefore warranted, but is
beyond the scope of this paper due to the number
of mAbs involved and the confidentiality surround-
ing the chimpanzee data.
The salient question from the perspective of this
review must be, Is the chimpanzee ever the only
“relevant” animal species and, if so, is it predictive
of, and relevant to, the human response to a degree
that means it is indispensable? Given the paucity
of chimpanzee data in the public domain, this is an
impossible question to answer; a fact acknowl-
edged by VandeBerg et al. when making their
claims of chimpanzee necessity, stating, “Some of
these antibodies [the 11 with FDA approval and
more than 400 others in clinical trials] were tested
in chimpanzees before they entered clinical trials
(proprietary data, unpublished). Data for antibod-
ies proposed for clinical trials (but not data for
antibodies that produced side-effects or were inef-
fective in chimpanzees), are supplied to the FDA.
However, these data are not published.” (6). 
To further illustrate this scarcity of data, a
search of the Oncology Tools section of the website
of the FDA’s Center for Drug Evaluation Research
(CDER: http://www.accessdata.fda.gov/scripts/cder/
onctools/) was performed, using the terms
‘Chimpanzee’ and ‘Troglodytes.’ The CDER is
charged with evaluating all new drug applications
in the United States before they can be sold, and
analyses all drug testing data supplied to it by
drug manufacturers. Its Oncology Tools website
serves as a repository of information regarding the
approval of new oncology drugs. This search pro-
duced just two results (both for infliximab
[Remicade]) — a remarkably low number of
results, given that several hundred mAbs have
been approved or are at least in clinical trials (6),
and the claims of the indispensable nature of chim-
panzee testing in this field. Further, these exam-
ples were identified because the drug is associated
with an increased risk of malignancies (168) not
detected in preclinical studies that involved chim-
panzees. The US Food and Drug Administration
(FDA) pharmacological review document (169)
states that chimpanzees were used in single and
multiple dose safety studies because they were the
only species in addition to humans whose TNF-
alpha (the target of the drug) bound infliximab.
Significant caveats were acknowledged however,
including the lack of histopathology data and the
limitation of study outcomes to clinically observ-
able signs only. Also, while chimpanzee pharmaco-
kinetic studies were performed, immunogenicity
assessments could not be made. 
It is pertinent to examine other NHP-related
publications regarding cancer mAb therapies, in
order to reveal which species of NHPs have been
used in the development, testing and characterisa-
tion of these mAbs (presumably in preference to
chimpanzees), and why. Cynomolgus monkeys,
plus a small number of vervet monkeys, were used
to test any (or all) of the general, developmental
and reproductive toxicities, and the pharmacoki-
netic/pharmacodynamic properties, of rituximab
(Rituxan; 170–174), tratsuzumab (Herceptin; 175,
176), alemtuzumab (Campath; 177–180), cetux-
imab (Erbitux; 181), bevacizumab (Avastin;
182–185) and panitumumab (Vectibix; 186). Just
two chimpanzee papers were associated with these
drugs, both of which were comparative genomics
studies that utilised chimpanzee DNA, as cited
earlier (92, 94). No NHP studies involving gem-
tuzumab (Mylotarg), ibritumomab tiuxetan
(Zevalin) or tositumomab (Bexxar) were identified.
Notably, a search of the scientific literature by
using the GoPubMed search engine (16) revealed
that, of more than 65,000 papers associated with
the ‘Neoplasms’ and ‘Antibodies, monoclonal’
MeSH terms, just 32 were associated with chim-
panzees (0.05%). This compares to more than
55,000 associated with humans (85%), 195 papers
with macaques, and 165 with vervet monkeys.
Further, only two of these 32 chimpanzee papers
have been published since 2002. If the use of chim-
panzees in this area represented necessary and
‘cutting edge’ science, one might have expected the
number of publications to be higher and to have
increased in recent years.
Support for and citations regarding the use of
chimpanzees in mAb testing were then sought in
review articles on mAb therapies published in
recent years. Kuroki et al. describe the develop-
ment of native and conjugated mAb therapies and
also antibody-directed gene therapies over the past
decade, with no citation of chimpanzee research or
testing (187). Schuster et al.’s general review,
Cancer Immunotherapy, does not mention chim-
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panzees (188), neither does Sharkey and Golden -
berg’s Targeted Therapy of Cancer: New Prospects
for Antibodies and Immunoconjugates (189), nor
Stern and Herrmann’s extensive Overview of
Monoclonal Antibodies in Cancer Therapy: Present
and Promise (190). 
Loisel et al. specifically reviewed the relevance,
advantages and limitations of animal models used
in cancer mAb development (191) and cited chim-
panzee experiments only twice, when discussing
antigen cross-reactivity and immunogenicity of
therapeutic mAbs in animals. The Loisel review
provided further caveats and limitations regarding
the use of NHP models, including chimpanzees.
The example of bevacizumab (Avastin) is given, for
which serious adverse reactions, including hyper-
tension, bleeding and thrombotic events, were not
predicted by NHP models, as well as the example
of trastuzumab (Herceptin), which is associated
with cardiotoxicity that also was not detected pre-
clinically (192). The review concludes that, “…it is
clear that performing preclinical studies of thera-
peutic antibodies in animals is no more than a
complex study of somewhat artificial interactions
of a xenogeneic protein with the host immune sys-
tem… Recent tragic events [TGN1412] show that
it is very difficult to circumvent many of those
drawbacks, and all these animal models [including
chimpanzees] must be considered as models only.”
The example of TGN1412, a monoclonal superag-
onist of the CD28 T-cell receptor intended for the
treatment of B-cell chronic lymphocytic leukaemia
(193), illustrates the difficulties of extrapolating pre-
clinical data to humans — even from NHPs that
demonstrate extremely encouraging pharmacoki-
netic and toxicological data and close homology of all
relevant molecules. Though tested in rhesus and
cynomolgus monkeys and not chimpanzees,
TGN1412 induced a systemic inflammatory
response in all six volunteers taking it in first-in-
human trials, despite being administered at a sub-
clinical dose some 500 times lower than the dose
found to be safe in animals (194). Multiple cytokine
release syndrome ensued, leading to multiple organ
failure and, in some cases, cardiovascular shock and
acute respiratory distress syndrome (195) — in com-
plete contrast to the NHP preclinical safety data. 
In May 2006, a workshop was conducted by the
UK’s National Centre for the Replacement,
Refinement and Reduction of Animals in Research
(NC3Rs) entitled, Opportunities for Reducing the
Use of Non-human Primates in the Development of
Monoclonal Antibodies (196). The report from this
workshop echoed concerns voiced over TGN1412
elsewhere, and identified opportunities to avoid
NHP use altogether in mAb development. They
cautioned that, while using chimpanzees might be
scientifically relevant, the “considerable ethical
concerns regarding the use of chimpanzees” mean
that “many in the pharmaceutical industry do not
see this as an option.” Data exist for 16 mAbs that
were licensed in the EU at the time of publication,
but just one of these, infliximab (Remicade), was
tested in chimpanzees, as discussed earlier.
Notably, the mouse was deemed the most relevant
species, alongside the chimpanzee, which was used
with surrogate antibodies to provide preclinical
safety and efficacy data. 
The author of the NC3Rs report subsequently
published a review on the subject of species rele-
vance in mAb testing, which concluded that, “…the
assumption that a shift from Old World primates
towards the use of chimpanzees might overcome
some of the issues associated with species rele-
vance is not necessarily supported by experts or
evidence. For example, some of the effects of
TGN1412 might have also been masked in the
chimpanzee owing to the human-specific loss of
expression of CD33-related Siglecs…also, the use
of chimpanzees for preclinical studies is restricted
by scientific, logistical and ethical problems, sug-
gesting that the chimpanzee might be of limited
value in the development of mAbs” (197).
Discussion and Conclusions
One would expect chimpanzees to have been used
widely in many, if not all, areas of cancer research,
due to ubiquitous claims of genetic similarity to
humans — a similarity that, prima facie, would
seem to underpin their suitability and relevance as
a model species for human disease research. This
genetic similarity forms the basis of recent claims,
for example, of the indispensability of chimpanzees
for the testing of monoclonal antibody therapies
(including those for cancer treatment), and for
their critical involvement in the development of
some such therapies to date (6).
A wider view of the nature of chimpanzee use,
however, would indicate that chimpanzees simply
cannot constitute a vital part of research into can-
cer, or indeed any other disease. Firstly, the gen-
eral importance of chimpanzee research was
assessed via an extensive citation analysis of
papers reporting chimpanzee data, and a detailed
evaluation of the contribution such papers have
made to human clinical progress and practice. Half
of a statistically-significant sample of 95 chim-
panzee papers had not been subsequently cited at
all. A further 35% were cited only by papers that
did not describe well-developed prophylactic, diag-
nostic or therapeutic methods for combating
human diseases. Less than 15% of chimpanzee
studies had been cited by papers that were rele-
vant to human medicine. An in-depth analysis of
these studies revealed that the chimpanzee exper-
iments had contributed very little, if anything at
all, to the outcome of those papers reporting an
advance in human clinical practice (7, 8). Secondly,
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of the approximate 1,000 chimpanzees remaining
in research laboratories in the United States, it is
believed only around 20% are in ‘active research
protocols’ and are merely being ‘warehoused’ (per-
sonal communication, J.L. VandeBerg (2008), at
the International Primatological Society Meeting,
Edinburgh, UK). Thirdly, over the last decade,
approximately 600 have been retired to sanctuar-
ies (198) and, in 2007, the US National Center for
Research Resources (NCRR), an institute under
NIH jurisdiction, chose to end federal funding for
breeding NCRR-owned or supported chimpanzees
for research, thus making the previous 10-year vol-
untary breeding moratorium permanent (199).
Finally, throughout the world, there has been a
steady and growing number of modern, scientifi-
cally advanced countries that have limited, termi-
nated or banned the use of chimpanzees and other
great apes in research (2). Most recently, in 2009,
an EU-wide ban on the use of chimpanzees and
other great apes was passed (200). None of these
trends would be seen if their use in research, can-
cer or otherwise, were crucial.
Further, and more specifically, this review deter-
mined that chimpanzees have scarcely been used
in any form of cancer research and that chim-
panzee tumours are both rare and biologically dif-
ferent from human cancers. Papers describing
potential new cancer therapies tested in chim-
panzees often included significant caveats based
on species differences, acknowledged that the
chimpanzee model performed no better than other
animal models, and/or described interventions that
had not been pursued clinically, presumably due to
adverse preclinical results. Notably, such studies
used very few chimpanzees — typically just four
animals per study (an average obtained from
papers cited in this review). This small sample size
casts doubt on the scientific significance of data
obtained from this research in any case. In the
field of mAb development, where chimpanzees
have been lauded as being of crucial importance,
available evidence clearly indicates that this is not
the case. Profound species differences in carcino-
genicity, cell growth, apoptosis and metastasis
demonstrate that chimpanzees constitute a poor
research model for human cancer, despite their
overall genetic similarity to humans.
Many papers, such as the series published by
Katoh & Katoh (82–101), described comparative
genomic studies in which human genes involved in
molecular pathways associated with cell
growth/differentiation and apoptosis were com-
pared to genes from other species, including chim-
panzees. Chimpanzee DNA was not central to
these studies, in which gene expression was
analysed between cancerous and normal tissue,
and promoter-binding sites, sequences and splicing
were compared between humans and a variety of
other species for evolutionary conservation, for
example. While it may be argued that this type of
investigation can be of relevance to human tumour
biology, it has no bearing on the use of captive
chimpanzee populations in laboratory research, as
they utilise readily available genetic material only.
Few papers described the investigation of new
therapeutic interventions, but these are of interest
due to poor interspecies extrapolation. Examples
reported include: recombinant TNF-related apopto-
sis-inducing ligand (119); inhibitor of TNF-alpha
converting enzyme (126); anti-angiotensin-convert-
ing enzyme antibodies (120); cell-based vaccines
(121, 123, 124, 139); and therapies targeting various
solid tumours, melanoma, and leukaemias (see
Results and Analysis section). No publications were
identified that described chimpanzee use in the
development or testing of mAb cancer therapies.
The underlying reasons for the lack of relevance
of chimpanzees to human cancer research, and
thus for their lack of utility and adoption as a can-
cer research model, lie in numerous fundamental
yet far-reaching genetic differences between chim-
panzees and humans that betray superficial claims
of genetic similarity. The consequences of differ-
ences in the prevalence of Alu sequences, siglec
expression, and other genetic differences are
described in detail in the Results and Analysis sec-
tion. Yet there are further differences: at least
twenty genes implicated in human cancers, some
of which are definitively involved in tumour for-
mation, are significantly different in chimpanzees
(48); other significant differences have been identi-
fied in protease genes, many of which affect the
immune system and that therefore have a poten-
tial bearing on tumour establishment and growth
(201); 80% of orthologous proteins differ between
humans and chimpanzees, including proteins
linked to breast cancer (202); and 6%–8% of orthol-
ogous exons display pronounced differences in
splicing, which affects diverse functions including
gene expression, signal transduction, cell death,
immune defence, and susceptibility to certain dis-
eases, including cancers (203).
A recent structural genomics study, which com-
pared the regulation of apoptosis between humans
and chimpanzees (204), acknowledged that nutri-
tional and ecological differences contributed to
changes in cancer incidence between the species, but
could not “coherently explain” an order of magnitude
increase in cancers of the breast, ovary, lung, stom-
ach, colon and rectum in humans (205). Instead, the
authors implicated some of the estimated 40 million
differences (of various types) between the human
and chimpanzee genomes, which determine suscep-
tibility and tolerance — as seen in different human
populations (206). The examination of around 500
proteins involved in apoptotic or DNA-repair path-
ways was revealing. Many protein-coding regions
were organised differently across the chromosomes
of each of the species. Some 5% of proteins analysed
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were expressed from genes with different numbers
of exons/different splice variants between the two
species, while more than 80 proteins from genes
with identical intron numbers were the products of
genes that had longer introns in chimpanzees — and
therefore probably more regulatory regions and
more regulatory RNA molecules affecting gene splic-
ing and expression. Around one tenth of the genes
involved in the analysis might be pseudogenes in the
chimpanzee. Further, there were, on average, more
than 2.5 splice variants per gene in the chimpanzee,
compared to 1.5 in humans, human proteins con-
tained a greater number of post-translational modi-
fication sites than the corresponding chimpanzee
proteins, and, despite a mean protein identity of 96%
between species, many proteins contained changes
that altered important protein–protein interactions
and/or compound-binding sites. To paraphrase the
authors’ conclusions, “a complex pattern of subtle
variances and a few large-scale changes on different
levels of chromosome organisation, gene structure,
post-transcriptional and post-translational modifica-
tions to functional changes in protein structures” is
responsible for the wholesale changes in carcino-
genicity between humans and chimpanzees.
It would therefore seem that Russell & Burch’s
“high-fidelity” fallacy (207) — the mistaken notion
that the more a model superficially resembles the
thing being modelled, the more suitable it is for
elucidating the phenomenon in question — is
highly applicable to cancer research in chim-
panzees, and indeed to chimpanzee research on
human diseases more generally. When our closest
genetic relative has contributed so little to combat-
ing cancers that have cost hundreds of millions of
lives and hundreds of billions of research dollars, it
is unscientific to claim that they must remain a
crucial and necessary tool in cancer research —
even in contemporary testing of mAb therapies. To
the contrary, there is no valid evidence to support
their use in the future, and it is reasonable to con-
clude that cancer research would not suffer if the
use of chimpanzees for this purpose were prohib-
ited in the USA.
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